Who is sponsoring NCT05910970?

NCT05910970 is sponsored by Guangxi Medical University.

What drugs are being tested in NCT05910970?

Interventions in NCT05910970: Adjuvant tislelizumab plus lenvatinib, Adjuvant tislelizumab.

What condition does NCT05910970 study?

NCT05910970 studies Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor.

Is NCT05910970 still recruiting?

NCT05910970 is currently status unknown. Last updated 23 January 2024.

Last reviewed 2024-01-23 · How we verify

NCT05910970: PREVENT-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation

Status unknown Phase 3 Last updated 23 January 2024

What this trial tests

Phase 3 trial testing Adjuvant tislelizumab plus lenvatinib in Hepatocellular Carcinoma in 200 participants. Status unknown.

Timeline

15 February 2024

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Guangxi Medical University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	15 February 2024
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

Adjuvant tislelizumab plus lenvatinib — full drug profile →
Adjuvant tislelizumab — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Recurrence — all drugs for Recurrence →
Immune Checkpoint Inhibitor — all drugs for Immune Checkpoint Inhibitor →

Sponsor

Guangxi Medical University

Who can join

Adults 18 to 70, any sex, with Hepatocellular Carcinoma or Recurrence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Though hepatic resection and ablation are the curative treatments for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%. In recent years, several immune checkpoint inhibitors have been approved in advanced or unresectable HCC. No study about the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with HCC after hepatectomy is reported.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models.
Desert R, Gianonne F, Saviano A, Hoshida Y, et al · · 2025 · cited 6× · PMID 40626281 · DOI 10.1038/s44355-025-00018-y
Small-molecule-based targeted therapy in liver cancer.
Ming Y, Gong Y, Fu X, Ouyang X, et al · · 2024 · cited 6× · PMID 39113358 · DOI 10.1016/j.ymthe.2024.08.001
Insights in Molecular Therapies for Hepatocellular Carcinoma.
Heumann P, Albert A, Gülow K, Tümen D, et al · · 2024 · cited 5× · PMID 38791911 · DOI 10.3390/cancers16101831
Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review.
Akabane M, Chatzipanagiotou OP, Imaoka Y, Schenk A, et al · · 2025 · cited 1× · PMID 40589998 · DOI 10.2147/itt.s528709

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Guangxi Medical University trials

Trials by the same sponsor.

NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT06851104 — A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence · Phase 2 · terminated
NCT05711823 — Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC · Phase 3 · unknown
NCT06161272 — Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi · Phase 2 · unknown
NCT05898256 — Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05910970 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangxi Medical University
Last refreshed: 23 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05910970.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing